Infinity Pharmaceuticals Inc.  

(Public, NASDAQ:INFI)   Watch this stock  
Find more results for INFI
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 8.80 - 18.25
Open     -
Vol / Avg. 0.00/663,755.00
Mkt cap 630.20M
P/E     -
Div/yield     -
EPS -1.39
Shares 49.04M
Beta 1.20
Inst. own 103%
Aug 3, 2015
Q2 2015 Infinity Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 15, 2015
Infinity Pharmaceuticals Inc Annual Shareholders Meeting - 8:30AM EDT - Add to calendar
May 18, 2015
Infinity Pharmaceuticals Inc at UBS Global Healthcare Conference
May 12, 2015
Infinity Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Infinity Pharmaceuticals Inc at Deutsche Bank Health Care Conference - Webcast
May 6, 2015
Q1 2015 Infinity Pharmaceuticals Inc Earnings Release
May 6, 2015
Q1 2015 Infinity Pharmaceuticals Inc Earnings Call - Webcast
Feb 25, 2015
Infinity Pharmaceuticals Inc at RBC Healthcare Conference
Feb 24, 2015
Q4 2014 Infinity Pharmaceuticals Inc Earnings Call - Webcast
Feb 24, 2015
Q4 2014 Infinity Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -2138.48% -10.56%
Operating margin -2122.74% -4.80%
EBITD margin - -3.73%
Return on average assets -117.54% -5.81%
Return on average equity -226.43% -8.48%
Employees 195 -
CDP Score - -


784 Memorial Dr
CAMBRIDGE, MA 02139-4613
United States - Map
+1-617-4531000 (Phone)
+1-617-4531001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Infinity Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing and delivering medicines to people with difficult-to-treat diseases. The Company develops small molecule drugs that target emerging disease pathways. The Company has worldwide development and commercialization rights to all of its development candidates and early discovery programs, subject to certain financial obligations to its current licensor and former development partners. The Company operates in one business segment, which focuses on drug discovery and development. IPI-145, the Company’s lead product candidate, is a potent, oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase, or PI3K, which the Company is investigating in both hematologic malignancies and inflammatory diseases. The PI3Ks are a family of enzymes involved in multiple cellular functions, including cell proliferation and survival, cell differentiation, cell migration and immunity.

Officers and directors

Adelene Q. Perkins Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Lawrence E. Bloch M.D., J.D. Chief Financial Officer, Executive Vice President, Chief Business Officer
Age: 50
Bio & Compensation  - Reuters
Julian Adams Ph.D. President - Research & Development
Age: 60
Bio & Compensation  - Reuters
Winston K C Lam Executive Vice President, General Counsel
Bio & Compensation  - Reuters
Sujay Kango Executive Vice President, Chief Commercial Officer
Bio & Compensation  - Reuters
Vito J. Palombella Ph.D. Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
David A. Roth M.D. Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Norman C. Selby Lead Outside Independent Director
Age: 62
Bio & Compensation  - Reuters
Jose Baselga M.D., Ph.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
Jeffrey Berkowitz J.D. Independent Director
Age: 49
Bio & Compensation  - Reuters